Skip to Main Content
Table 6.

Odds ratios (95 % CI) for ER-defined breast cancer across plasma enterolactone concentration (low/high) in women from the MDC cohort, 1991 to 2004

ENL concentration
P for heterogeneity
LowHigh
ENL concentration (nmol/L), median (range) 8.4 (0.3-16.1) 26.3 (16.1-334.4)  
    Cases/controls 204/366 162/367  
    OR (95% CI) 1.00 0.75 (0.58-0.98)  
    ERα (−) tumors    
        Cases/controls 27/366 25/367  
        OR (95% CI) 1.00 0.86 (0.48-1.54)  
    ERα (+) tumors    
        Cases/controls 175/366 134/367  
        OR (95% CI) 1.00 0.73 (0.55-0.97) 0.62* 
    ERβ (−) tumors    
        Cases/controls 113/366 72/367  
        OR (95% CI) 1.00 0.60 (0.43-0.85)  
    ERβ (+) tumors    
        Cases/controls 91/366 90/367  
        OR (95% CI) 1.00 0.94 (0.67-1.33) 0.04 
    ERα (+)/ERβ (−) tumors    
        Cases/controls 93/366 59/367  
        OR (95% CI) 1.00 0.59 (0.41-0.86)  
    ERα (+)/ERβ (+) tumors    
        Cases/controls 82/366 75/367  
        OR (95 % CI) 1.00 0.90 (0.63-1.28) 0.08 
ENL concentration
P for heterogeneity
LowHigh
ENL concentration (nmol/L), median (range) 8.4 (0.3-16.1) 26.3 (16.1-334.4)  
    Cases/controls 204/366 162/367  
    OR (95% CI) 1.00 0.75 (0.58-0.98)  
    ERα (−) tumors    
        Cases/controls 27/366 25/367  
        OR (95% CI) 1.00 0.86 (0.48-1.54)  
    ERα (+) tumors    
        Cases/controls 175/366 134/367  
        OR (95% CI) 1.00 0.73 (0.55-0.97) 0.62* 
    ERβ (−) tumors    
        Cases/controls 113/366 72/367  
        OR (95% CI) 1.00 0.60 (0.43-0.85)  
    ERβ (+) tumors    
        Cases/controls 91/366 90/367  
        OR (95% CI) 1.00 0.94 (0.67-1.33) 0.04 
    ERα (+)/ERβ (−) tumors    
        Cases/controls 93/366 59/367  
        OR (95% CI) 1.00 0.59 (0.41-0.86)  
    ERα (+)/ERβ (+) tumors    
        Cases/controls 82/366 75/367  
        OR (95 % CI) 1.00 0.90 (0.63-1.28) 0.08 

NOTE: Adjusted for age, date of blood collection, weight, height, smoking status, educational status, and current use of menopausal hormone therapy.

*

Test of heterogeneity between ERα (−) and ERα (+) tumors.

Test of heterogeneity between ERβ (−) and ERβ (+) tumors.

Test of heterogeneity between ERα (+)/ERβ (−) and ERα (+)/ERβ (+) tumors.

Close Modal

or Create an Account

Close Modal
Close Modal